LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company focused on telehealth infrastructure for emerging markets, announced it expects to submit a corporate action request to FINRA today seeking approval for a five-for-one forward stock split. The proposed split would also proportionally increase the company's authorized common and preferred stock.
The company stated that the forward stock split is intended to support long-term operational scalability, strategic flexibility, and future growth initiatives as it continues deploying telehealth infrastructure and healthcare analytics platforms throughout Latin America and other emerging markets. LataMed AI recently commenced initial operational activities for its telehealth platform in Venezuela after receiving regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS).
Management emphasized that the proposed corporate action does not involve debt restructuring, recapitalization, or reduction in shareholder ownership percentages. No fractional shares are expected to be issued; any fractional interests would be rounded up to the nearest whole share. The split applies to all issued and outstanding common shares and preferred stock designations, including the Series C Voting Preferred Stock.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform.”
The company noted that the forward stock split is part of a broader effort to align its capital structure with its transition into digital healthcare infrastructure and AI-driven telehealth operations. The proposal is subject to FINRA review and approval, completion of regulatory processing, and final corporate implementation procedures. No assurance can be provided regarding the timing or ultimate effectiveness of the proposed action.
LataMed AI Corp. is a development-stage enterprise that has not generated revenues from its current business operations. The company is advancing a technology-enabled healthcare ecosystem designed to support remote patient engagement, provider coordination, healthcare analytics, and broader digital healthcare delivery initiatives. For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
